Skip to main content
Clinical Trials/NCT05130034
NCT05130034
Completed
N/A

Home-based Pulmonary Rehabilitation and Health Coaching to Improve Respiratory-related Quality of Life and Physical Activity in Fibrotic Interstitial Lung Disease

Mayo Clinic1 site in 1 country81 target enrollmentDecember 13, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Fibrotic Interstitial Lung Disease
Sponsor
Mayo Clinic
Enrollment
81
Locations
1
Primary Endpoint
Physical activity
Status
Completed
Last Updated
12 months ago

Overview

Brief Summary

The purpose of this study is to gather information on the effectiveness of a home-based pulmonary rehabilitation program with health coaching and tele-monitoring for improving patient-reported respiratory-related quality of life and physical activity in patients with fibrotic Interstitial Lung Diseases (f-ILD).

Detailed Description

The home-based pulmonary rehabilitation program involves using a computer tablet paired with a pulse oximeter and activity tracker. Gentle upper body exercises, walking and a breathing practice are completed by following along on the computer tablet. Weekly check-in calls by telephone will be provided by a Health Coach to assess clinical status and monitor progress. The exercise portion of the program lasts 12 weeks. There are questionnaires and a research grade activity tracker measuring baseline and post-intervention findings at the end of 12-week period.

Registry
clinicaltrials.gov
Start Date
December 13, 2021
End Date
April 15, 2025
Last Updated
12 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Teng Moua

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of idiopathic pulmonary fibrosis (IPF) or other fibrotic interstitial lung disease, with a minimum of \> 10% fibrosis on computed tomography imaging.
  • Clinically meaningful breathlessness: modified Medical Research Council (mMRC) dyspnea score \>1.

Exclusion Criteria

  • Inability to walk (orthopedic/neurologic/cardiac limitation causing immobility).
  • Cognitive impairment or inability to understand and follow instructions.
  • Traditional PR completed within 3 months of study recruitment.
  • Hospice or end-of-life care at the time of screening.
  • Acute exacerbation at the time of screening.

Outcomes

Primary Outcomes

Physical activity

Time Frame: Baseline, 12 weeks

Measured by mean number of steps per 24-hour period as assessed by Actigraphy, pre- and post-intervention

Change in patient-reported respiratory-related quality of life CRQ Physical Summary score

Time Frame: Baseline, 12 weeks

Measured using the Chronic Respiratory Questionnaire (CRQ) survey which is a validated tool for measuring health status in patients with chronic lung disease divided into four domains of dyspnea, fatigue, emotion, and mastery. The Physical Summary score combines dyspnea and fatigue dimensions, a lower score suggests a greater degree of dysfunction on a 7-point scale. A difference of 0.5 in any domain is considered clinically significant (the minimal clinically important difference (MCID)). Higher total scores represent relatively better or improved patient-reported quality of life.

Change in patient-reported respiratory-related quality of life CRQ Emotional score

Time Frame: Baseline, 12 weeks

Measured using the Chronic Respiratory Questionnaire (CRQ) survey which is a validated tool for measuring health status in patients with chronic lung disease divided into four domains of dyspnea, fatigue, emotion, and mastery. The emotional domain score is measured by a lower score suggests a greater degree of dysfunction on a 7-point scale. A difference of 0.5 in any domain is considered clinically significant (the minimal clinically important difference (MCID)). Higher total scores represent relatively better or improved patient-reported quality of life.

Secondary Outcomes

  • Self-reported tolerance of directed medical management(Baseline, 12 weeks)
  • Qualitative assessment of patient-reported efficacy(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials